Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Obexelimab · XMAB-5871

Monoclonal antibody · Modulator of CD19 and Fc gamma receptor IIB (CD32B) (FCGR2B) · developed by Zenas BioPharma, LLC

Phase 3 Most advanced trial
ZBIO Developer
2 Registered trials

What is Obexelimab?

Obexelimab is a humanized, Fc-engineered monoclonal antibody that simultaneously binds CD19 and Fc gamma receptor IIB on B cells. By engaging both, it inhibits B-cell receptor signaling and B-cell activity without depleting the cells. It is being studied in warm autoimmune hemolytic anemia and systemic lupus erythematosus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XMAB-5871
Drug type
Monoclonal antibody
Targets
CD19, Fc gamma receptor IIB (CD32B) (FCGR2B)
Mechanism
Modulator of CD19 and Fc gamma receptor IIB (CD32B) (FCGR2B)
Pathways
B-cell receptor signaling
Therapy area
Immunology
Developer
Zenas BioPharma, LLC (ZBIO)
Also in trials of
XNCR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
RM16A4BA8R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05786573 Phase 3 Warm Autoimmune Hemolytic Anemia Active not recruiting ZBIO
NCT02725515 Phase 2 Systemic Lupus Erythematosus Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Warm Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus

Other drugs acting on CD19 / FCGR2B

More from Zenas BioPharma, LLC

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZBIO page.

Follow ZBIO, the company behind Obexelimab

See ZBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZBIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.